Vidac Pharma Holdings Plc. Hits LPLV in Phase 2b AK Trial; Data Analysis Next
Vidac Pharma completed the last patient's last visit in its randomized, double-blind, placebo-controlled Phase 2b study of topical VDA-1102 in highly proliferative actinic keratosis. Final data review is underway; results, including biopsy analyses, are expected in the coming weeks.Material Details…